Literature DB >> 8133902

COMT inhibitors and metabolism of fluorodopa enantiomers in aggregating cell cultures.

C Wiese1, M Cogoli-Greuter, R Weinreich, K H Winterhalter.   

Abstract

Organotypic primary cell cultures of fetal rat brain were used as a model system to study the effect of COMT inhibitors on the cerebral metabolic conversions of fluoro-DOPA enantiomers. The selective COMT inhibitors OR 486 and CGP 28014 were used in conjunction with 5F-L-DOPA, 6F-L-DOPA and 6F-D-DOPA as substrates. Methylation can be clearly reduced by application of OR 486 at nanomolar level, without inhibition of AADC and MAO. The uptake of the substrate is unchanged. CGP 28014, already known to be active only in vivo, has no influence on the metabolic conversion rates of the fluoro-DOPA isomers. These results show that use of this culture system allows statement concerning the in vitro activity of COMT inhibitors. It has not been possible to show an increase of absolute levels of decarboxylation products due to inhibition of COMT, however, but the reduction in levels of methylated product itself may have significance for PET studies of the human brain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8133902     DOI: 10.1007/bf00167233

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  13 in total

1.  3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

Authors:  L A Wade; R Katzman
Journal:  Life Sci       Date:  1975-07-01       Impact factor: 5.037

Review 2.  New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

Authors:  P T Männistö; S Kaakkola
Journal:  Trends Pharmacol Sci       Date:  1989-02       Impact factor: 14.819

3.  Protein determination in membrane and lipoprotein samples: manual and automated procedures.

Authors:  M A Markwell; S M Haas; N E Tolbert; L L Bieber
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.

Authors:  P Cumming; B E Boyes; W R Martin; M Adam; T J Ruth; E G McGeer
Journal:  Biochem Pharmacol       Date:  1987-08-01       Impact factor: 5.858

5.  Metabolism of 5-fluoro-dopa and 6-fluoro-dopa enantiomers in aggregating cell cultures of fetal rat brain.

Authors:  C Wiese; M Cogoli-Greuter; M Argentini; T Mäder; R Weinreich; K H Winterhalter
Journal:  Biochem Pharmacol       Date:  1992-07-07       Impact factor: 5.858

6.  Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.

Authors:  P C Waldmeier; P De Herdt; L Maitre
Journal:  J Neural Transm Suppl       Date:  1990

7.  Determination of dopa, dopamine, dopac, epinephrine, norepinephrine, alpha-monofluoromethyldopa and alpha-difluoromethyldopa in various tissues of mice and rats using reversed-phase ion-pair liquid chromatography with electrochemical detection.

Authors:  J Wagner; M Palfreyman; M Zraika
Journal:  J Chromatogr       Date:  1979-09-11

8.  Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.

Authors:  E Nissinen; I B Lindén; E Schultz; S Kaakkola; P T Männistö; P Pohto
Journal:  Eur J Pharmacol       Date:  1988-08-24       Impact factor: 4.432

9.  Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum.

Authors:  A Reches; D Jiang; S Fahn
Journal:  Biochem Pharmacol       Date:  1982-11-01       Impact factor: 5.858

10.  Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain.

Authors:  A J Rivett; A Francis; J A Roth
Journal:  J Neurochem       Date:  1983-01       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.